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acqueline Saw, MD, Cameron Densem, MD, Simon Walsh, MD, Percy Jokhi, MD, PHD,
ndrew Starovoytov, MD, Rebecca Fox, MSC, Graham Wong, MD,
hristopher Buller, MD, Donald Ricci, MD, G. B. John Mancini, MD,
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bjectives The purpose of this study was to evaluate the effects of aspirin and clopidogrel re-
ponse on myonecrosis after percutaneous coronary intervention (PCI) with glycoprotein (GP) IIb/IIIa
lockade.
ackground Aspirin and clopidogrel resistance is increasingly recognized, but its effects on PCI out-
omes with GP IIb/IIIa blockade are unknown.
ethods This was a prospective, pre-speciﬁed substudy of the BRIEF-PCI (Brief Infusion of Intrave-
ous Eptiﬁbatide Following Successful Percutaneous Coronary Intervention) trial, which randomized
24 patients to 18-h or 2-h eptiﬁbatide infusion after uncomplicated PCI. To be eligible, patients
ust have been pre-treated with aspirin (5 days) and clopidogrel (75 mg/day 5 days, 300 mg
oading 6 h, or 600 mg loading 2 h) and must not have received GP IIb/IIIa inhibitors within
8 h. Verify-Now Aspirin and Clopidogrel (P2Y12) assays were performed at baseline before PCI.
atients with aspirin reaction unit (ARU) 550 were labeled as aspirin resistant. Clopidogrel low-
esponders were deﬁned as those in the lowest quartile of platelet inhibition. The primary end point
as the prevalence of myonecrosis within 24 h after PCI.
esults We enrolled 209 patients into our substudy, of which 185 had aspirin response assessed,
98 had clopidogrel response assessed, and 174 had both assessed. There were 4.9% who were as-
irin resistant. Clopidogrel low-responders were deﬁned as those in the lowest quartile with platelet
nhibition 19%. Only 1.1% had both aspirin resistance and low clopidogrel response. There was no
ifference in myonecrosis prevalence among aspirin-resistant compared with aspirin-sensitive pa-
ients (11.1% vs. 27.8%, p  0.259) or among clopidogrel low-responders compared with clopidogrel
esponders (23.5% vs. 29.3%, p  0.433).
onclusions Aspirin and clopidogrel response did not affect myonecrosis prevalence amongst pa-
ients who received eptiﬁbatide for PCI. (J Am Coll Cardiol Intv 2008;1:654–9) © 2008 by the
merican College of Cardiology Foundation
rom the Division of Cardiology, Vancouver General Hospital, University of British Columbia, Vancouver, British Columbia,
anada.anuscript received July 2, 2008; revised manuscript received August 14, 2008, accepted August 23, 2008.
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Aspirin and Clopidogrel Response on PCI Outcomes
655ariability in response to aspirin and clopidogrel is increas-
ngly recognized in cardiovascular medicine. However, the
linical relevance and importance of this variability and
onresponse to these agents remain contentious. Further-
ore, there is no established standard for tests for diagnos-
ng antiplatelet therapy nonresponse. Several central labo-
atory and point-of-care assays have been used to assess
arying physiologic aspects of platelet response to these
gents. However, none of these tests correlate well with
ach other for diagnosing nonresponse, and none have
efinitively been shown to predict adverse clinical events
hen nonresponse was found. Nevertheless, such technical
imitations have not dampened the enthusiasm of clinicians
o identify patients with suboptimal antiplatelet response,
ecause the potential consequence of nonresponse could be
catastrophic cardiovascular event.
See page 660
The enthusiasm to evaluate aspirin and clopidogrel response
s most compelling in the setting of interventional cardiology,
ecause both these agents are used adjunctively after coronary
tent placement to prevent stent thrombosis. There have been
recent publications that evaluated myonecrosis prevalence
fter percutaneous coronary intervention (PCI) according to
spirin and clopidogrel response, but controversial results were
eported (1–3). Notably, none of the patients in these studies
eceived a glycoprotein (GP) IIb/IIIa inhibitor during the PCI.
his is pertinent, because GP IIb/IIIa inhibitors are potent
latelet antagonists that are frequently used as a component of
he “triple antiplatelet armamentarium” during PCI to reduce
eriprocedural cardiovascular events. We hypothesized that
P IIb/IIIa blockade would minimize any clinical impact of
spirin and clopidogrel nonresponse. We therefore evaluated
he effects of aspirin and clopidogrel response on the prevalence
f myonecrosis after PCI in the presence of GP IIb/IIIa
lockade.
ethods
e designed a prospective, pre-specified substudy of the
RIEF-PCI (Brief Infusion of Intravenous Eptifibatide
ollowing Successful Percutaneous Coronary Intervention)
rial, because all patients received a GP IIb/IIIa inhibitor. In
hort, the BRIEF-PCI trial was a randomized, double-
linded controlled trial comparing an abbreviated 2-h
nfusion of eptifibatide (Integrilin, Schering Corporation,
enilworth, New Jersey) with a standard 18-h infusion
mong 624 patients who underwent an uncomplicated PCI
4). To be eligible for this substudy, patients must have been
re-treated with aspirin (81 to 325 mg daily for at least 5
ays) and clopidogrel (received 75 mg/day for 5 days or
00-mg loading dose 6 h prior or 600-mg loading dose
2 h prior). Patients were excluded if they received a GP RIb/IIIa inhibitor within 48 h; had a recent (48 h)
T-segment elevation myocardial infarction (MI); had vis-
ble coronary thrombus; received bivalirudin; required un-
rotected left main intervention; required use of ablative or
hrombectomy devices; had allergy or intolerance to aspirin,
hienopyridines, or eptifibatide; or had unsatisfactory PCI
esults. Anticoagulant during the PCI was either unfrac-
ionated heparin (50 to 70 IU/kg) or enoxaparin. Intrave-
ous eptifibatide was administered before the first balloon
nflation as a double-bolus of 180 g/kg (10 min apart)
ollowed by an infusion of 2 g/kg/min.
The VerifyNow Aspirin and Clopidogrel (P2Y12) assays
Accumetrics Inc., San Diego, California) were performed
t baseline before PCI and administration of eptifibatide.
hole blood samples were collected into Vacuette tubes
Gernie, Monroe, North Carolina) containing 3.2% sodium
itrate. The sample tubes were gently inverted several times
nd incubated at room temperature for at least 10 min. The
ssay cartridges were then inserted into the instrument,
ollowed by the insertion of the sample tubes into the
artridges. These assay car-
ridges contain fibrinogen-
oated beads and platelet ago-
ists (the aspirin assay contains
rachidonic acid, and the clo-
idogrel assay contains adeno-
ine diphosphate [ADP]/
rostaglandin E1 [PGE1] and
sothrombin receptor activating
rotein [TRAP]). Activated
latelets in whole blood bind
nd aggregate the fibrinogen-
oated beads in proportion to
he number of expressed GP
Ib/IIIa receptors, with consequent increase in light trans-
ittance. This change in optical signal is reported as aspirin
eaction unit (ARU) and P2Y12 reaction unit by the aspirin
nd clopidogrel assays, respectively. The P2Y12 assay also
eports “percent inhibition (%),” which is the percent
hange from baseline aggregation calculated from the P2Y12
eaction unit result and the baseline result from the TRAP
hannel. Patients with ARU 550 were labeled as aspirin
esistant. Clopidogrel low-responders were defined as those
elonging to the lowest quartile of platelet inhibition.
Laboratory tests including troponin-I (Tn-I), total creatine
inase, and creatine kinase-myocardial band (CK-MB) were
erformed at baseline, at 6 to 8 h after PCI, and the following
ay (18 to 24 h). Patients were followed by a research
oordinator during hospital stay and contacted by telephone at
0 days. The study protocol was approved by the University of
ritish Columbia Ethics Review Board, and all patients pro-
ided written informed consent before participation in the
tudy. The study was funded by Interventional Cardiology
Abbreviations
and Acronyms
ARU  aspirin reaction unit
CK-MB  creatine kinase-
myocardial band
GP  glycoprotein
PCI  percutaneous
coronary intervention
TRAP  thrombin receptor
activating protein
Tn-I  troponin-Iesearch at Vancouver General Hospital.
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656The primary end point was the prevalence of myonecrosis
ithin 24 h after PCI, which was defined as Tn-I elevation
0.26 g/L in patients with normal baseline Tn-I. In
atients with elevated baseline Tn-I, CK-MB 3 times
pper limit of normal and 50% above baseline was used.
e also assessed secondary end points of CK-MB elevation
3 times upper limit of normal, clinical end point of death,
I, and urgent target vessel revascularization at 30 days,
EPLACE-2 (Randomized Evaluation in PCI Linking
ngiomax to Reduced Clinical Events) major and minor
leeding events (5), and blush score before and after
CI (6).
tatistical analysis. Hypothesis tests were done with 2-sided
ests at the 5% significance level. Baseline characteristics
ere compared with chi-square and Fisher exact tests for
iscrete variables and Wilcoxon rank-sum test for continu-
us variables. Statistical comparisons of primary and sec-
ndary end points were performed with Pearson’s chi-
Table 1. Baseline Characteristics
Characteristics,
% (n) or Mean  SD
All Patients
(n  209)
Aspirin Resistant
(n  9)
Age (yrs) 61.3 9.9 63.6 10.9
Male 80.9% (169) 88.9% (8)
Body mass index (kg/m2) 28.4 5.0 29.1 7.1
Prior PCI 22.5% (47) 22.2% (2)
Prior CABG 4.8% (10) 0.0% (0)
Prior MI 30.6% (64) 33.3% (3)
Diabetes mellitus 14.8% (31) 22.2% (2)
Hypertension 57.4% (120) 66.7% (6)
Hyperlipidemia 78.9% (165) 88.9% (8)
Active smoker 23.0% (48) 44.4% (4)
PAD 5.3% (11) 11.1% (1)
ACS 57.4% (120) 44.4% (4)
Baseline laboratory results
Creatinine 93.1 20.5 91.0 17.3
Hemoglobin 144.4 13.8 141.5 12.2
Platelet 237.6 58.9 248.9 67.5
CRP 7.0 14.6 7.0 7.7
Pre-procedural medications
CCB 16.7% (35) 0.0% (0)
ACE inhibitors 71.3% (149) 66.7% (6)
Beta blockers 90.9% (190) 88.9% (8)
Statins 87.6% (183) 66.7% (6)
Procedural characteristics
Integrilin 18 h 49.3% (103) 66.7% (6)
Integrilin duration (h) 8.9 8.3 12.1 8.4
# of vessels treated 1.3 0.5 1.2 0.4
# of lesions treated 1.7 0.9 1.4 0.7
DES used 36.8% (77) 33.3% (3)
AHA B2 or C lesion 64.8% (114) 44.4% (4)
*p 0.05.
ACE angiotensin-converting enzyme; ACS acute coronary syndrome; AHA American Heaprotein; DES drug-eluting stent; MImyocardial infarction; PAD peripheral arterial disease.quare test for categorical data and Mann Whitney test for
ontinuous variables. Interactions were tested with logistic
egression, incorporating terms for randomized treatment
ssignment (abbreviated vs. standard eptifibatide duration),
spirin response, and clopidogrel response. A sample size of
04 was determined to be required—assuming clopidogrel
ow-responder prevalence of 25% and myonecrosis preva-
ence of 40% after PCI in responders—to detect an absolute
ifference of 20% from low-responders, with 5% alpha and
0% power. The SPSS 13.0 statistical software (SPSS,
hicago, Illinois) was used.
esults
e enrolled 209 patients into the BRIEF-PCI substudy
rom March 2005 to May 2007 at the Vancouver General
ospital, British Columbia, Canada. All patients received
ntravenous eptifibatide. Of these patients, 185 had baseline
in Sensitive
 176)
Clopidogrel Low-Responder
(n  51)
Clopidogrel Responder
(n  147)
1.1 10.0 60.6 9.5 61.8 10.2
.3% (143) 82.4% (42) 82.3% (121)
8.3 4.7 30.3 5.3* 27.8 4.7*
.2% (39) 29.4% (15) 19.7% (29)
.1% (9) 7.8% (4) 2.7% (4)
.7% (54) 39.2% (20) 27.9% (41)
.2% (25) 19.6% (10) 14.3% (21)
.0% (102) 64.7% (33) 53.7% (79)
.5% (140) 68.6% (35) 82.3% (121)
.2% (39) 21.6% (11) 23.8% (35)
.3% (11) 2.0% (1) 6.8% (10)
.1% (104) 60.8% (32) 53.7% (79)
3.0 20.7 98.2 23.9 91.6 19.7
4.4 13.8 146.0 15.8 143.9 13.3
6.4 59.4 222.9 56.1 242.8 60.2
7.2 16.1 14.7 25.9* 4.5 6.7*
.9% (28) 17.6% (9) 17.0% (25)
.2% (127) 72.5% (37) 70.1% (103)
.2% (164) 98.0% (50)* 87.8% (129)*
.2% (157) 88.2% (45) 87.8% (129)
.0% (88) 52.9% (27) 48.3% (71)
9.0 8.3 9.2 8.3 8.7 8.3
1.3 0.5 1.3 0.6 1.2 0.5
1.7 1.0 1.9 1.2 1.6 0.8
.8% (63) 39.2% (20) 36.7% (54)
.7% (114) 61.0% (25) 66.4% (83)
iation; CABG coronary artery bypass surgery; CCB calcium-channel blocker; CRP C-reactiveAspir
(n
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657spirin response assessed, 198 had clopidogrel response
ssessed, and 174 had both assessed. The baseline charac-
eristics are reported in Table 1, with patients segregated
nto groups according to aspirin and clopidogrel response.
spirin-resistant patients had similar baseline characteris-
ics compared with aspirin-sensitive patients. Clopidogrel
ow-responders tended to have higher body-mass index,
igher baseline C-reactive protein level, and greater beta-
lockade use, compared with clopidogrel responders. The
ajority of our patients received clopidogrel 75 mg/day for
t least 5 days (78.9%). Only 13.9% received clopidogrel
00-mg loading at least 6 h previously, and only 7.2%
eceived clopidogrel 600-mg loading at least 2 h previously.
According to our criteria, 4.9% of patients were aspirin
esistant. Figure 1 shows the distribution of ARU in our
ubstudy patients. Clopidogrel low-responders were defined
s those belonging to the lowest quartile with platelet
nhibition 19% (Fig. 2). Only 1.1% of patients were both
spirin resistant and clopidogrel low-responders. There was
o difference in the primary end point of myonecrosis
mong aspirin-resistant compared with aspirin-sensitive
atients (11.1% vs. 27.8%, p 0.259) or among clopidogrel
ow-responders compared with clopidogrel responders
23.5% vs. 29.3%, p  0.433) (Table 2).
We also segregated aspirin and clopidogrel response into
uartiles of ARU and platelet inhibition, respectively, and
ound no difference in the prevalence of myonecrosis be-
ween different quartiles (Figs. 3 and 4). Likewise, there was
o difference among patients who received different clopi-
ogrel loading regimens (75 mg/day for5 days or 300-mg
oading dose 6 h prior or 600-mg loading dose 2 h
Figure 1. Aspirin Response
Distribution of the aspirin reaction unit (ARU) with the VerifyNow Aspirin(
assay.rior), with respect to platelet inhibition achieved (p 
.839) or prevalence of myonecrosis with PCI (p  0.985).
There were also no differences in the secondary end points of
K-MB elevation, clinical 30-day death, MI and urgent
arget vessel revascularization event-rates, REPLACE-2
ajor or minor bleeding events (Table 2), and blush score
efore and after PCI, when comparing between aspirin-
esistant and -sensitive patients and between clopidogrel
ow-responders and responders.
Because patients were randomized to different durations
f eptifibatide infusion, we tested for interactions between
he randomized assignment of eptifibatide duration (2 h
s. 18 h) and aspirin and clopidogrel response. We found no
ignificant interaction between aspirin resistance and ran-
omized treatment (p  0.999) or between clopidogrel
ow-response and randomized treatment (p 0.448) on the
revalence of myonecrosis.
iscussion
ur study demonstrated that the prevalence of myonecrosis
as not affected by the response to aspirin and clopidogrel
mongst patients who also received eptifibatide during PCI.
ikewise, the short-term clinical event-rates were not af-
ected by aspirin and clopidogrel response in this cohort.
herefore, it seems that the effects of GP IIb/IIIa blockade
ith eptifibatide were sufficiently potent such that even lack
f adequate response to aspirin and/or clopidogrel before
CI did not jeopardize the short-term results of PCI.
Aspirin and clopidogrel resistance had been associated
ith higher rates of adverse clinical outcomes after PCI
Figure 2. Clopidogrel Response
Distribution of platelet inhibition (%) with the VerifyNow Clopidogrel
(P2Y12) assays. Patients in the lowest quartile had 19% platelet inhibition.1,2). However, our study suggests that the clinical impact
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658f aspirin or clopidogrel resistance was blunted amongst
atients undergoing PCI who also received GP IIb/IIIa
nhibitors. This suggests that routine evaluation for aspirin
r clopidogrel response might not be necessary in this
ohort. Correspondingly, a GP IIb/IIIa inhibitor could be
sed to ensure low periprocedural myonecrosis and clinical
dverse events in patients in whom aspirin and/or clopi-
ogrel resistance is suspected.
Our study expands on the 3 previously published studies
n this topic, none of which incorporated the use of GP
Ib/IIIa inhibitors (1–3). Moreover, these previous trials
ave demonstrated conflicting results with respect to the
mpact of aspirin and clopidogrel resistance on the preva-
ence of myonecrosis after PCI. Chen et al. (1) assessed 151
atients who underwent nonurgent PCI and found 19.2% of
atients to be aspirin resistant on the basis of the Accumet-
ics VerifyNow Aspirin assay. Compared with patients who
ere aspirin responders, aspirin-resistant patients did have a
igher prevalence of CK-MB and Tn-I elevation after PCI.
ev et al. (2) assessed 150 patients who underwent
Figure 3. ARU Quartiles and Myonecrosis Prevalence
Prevalence of myonecrosis according to quartiles of aspirin reaction unit
Table 2. Prevalence of Myonecrosis and Secondary End Points
Aspirin Resistant Aspirin Sensitive
Myonecrosis 11.1% (1/9) 27.8% (49/176)
CK-MB 3 ULN 11.1% (1/9) 2.3% (4/176)
REPLACE-2 major bleeding 0.0% (0/9) 2.3% (4/176)
REPLACE-2 minor bleeding 22.2% (2/9) 22.2% (39/176)
30-day death, MI, urgent TVR 11.1% (1/9) 2.3% (4/176)
CK-MB creatine kinase-myocardial band; MImyocardial infarction; REPLACE Randomized Ev
upper limit of normal.(ARU) with the VerifyNow Aspirin assay.lective PCI. They found 12.7% of patients to be aspirin
esistant with both the VerifyNow Aspirin assay and light
ransmittance aggregometry. They also found 24% of pa-
ients to be clopidogrel resistant with light transmittance
ggregometry. Aspirin-resistant patients had a higher prev-
lence of CK-MB elevation after PCI; however, there was
nly a trend to higher prevalence of CK-MB elevation in
lopidogrel-resistant patients. Finally, Buch et al. (3) as-
essed 330 patients who underwent elective PCI. They
ound no correlation between aspirin and clopidogrel re-
ponse to Tn-I or CK-MB release with PCI, with the
erifyNow Aspirin and P2Y12 assays.
We used the VerifyNow Aspirin and P2Y12 assays to
ssess for aspirin and clopidogrel response, because these
ssays have been approved for clinical use, with rcal useesults
hat are rapidly available at the bedside and require minimal
echnical manipulation of the whole blood samples. With
his assay, we found that only approximately 5% of our
atient population was aspirin resistant (ARU 550).
Figure 4. Platelet Inhibition Quartiles and Myonecrosis Prevalence
Prevalence of myonecrosis according to quartiles of platelet inhibition with
the VerifyNow Clopidogrel (P2Y12) assays (1st quartile corresponds to the
ue Clopidogrel Low Responder Clopidogrel Responder p Value
9 23.5% (12/51) 29.3% (43/147) 0.433
2 3.9% (2/51) 2.1% (3/146) 0.467
8 3.9% (2/51) 2.7% (4/147) 0.667
6 17.6% (9/51) 29.3% (43/147) 0.125
2 2.0% (1/51) 2.7% (4/147) 0.766
in PCI Linking Angiomax to Reduced Clinical Events; TVR target vessel revascularization; ULNp Val
0.25
0.11
0.64
0.99
0.11
aluationlowest quartile of platelet inhibition).
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659owever, there is no manufacturer’s threshold identified for
lopidogrel resistance. Thus, we allocated measured platelet
nhibition into quartiles, and clopidogrel low-responders
ere defined as those belonging to the lowest quartile of
latelet inhibition. With these definitions, we found that
nly 1.1% of patients were both aspirin resistant and a
ow-responder to clopidogrel.
tudy limitations. We included only a small patient popu-
ation in our substudy. The observed prevalence of myone-
rosis (28.2% in this substudy) was lower than anticipated,
nd thus the lack of difference in myonecrosis prevalence
etween the groups evaluated might be due to the study
eing underpowered. Moreover, the lower prevalence of
spirin resistance (4.9%) in our patient population further
educed our study’s power to assess aspirin-resistant pa-
ients. We could only use the VerifyNow assays for aspirin
nd clopidogrel response, due to funding limitations. We
id not use light transmittance aggregometry to assess for
spirin and clopidogrel platelet response, because this tech-
ique requires a designated platelet laboratory with dedi-
ated technical personnel to prepare platelet rich plasma,
hich are both time intensive and costly. Likewise, we did
ot perform flow-cytometry assessments of platelet receptor
xpression or use other point-of-care devices (e.g., PFA-
00) due to cost constraints. Several authors have shown
hat platelet function tests correlate poorly amongst them-
elves (7–9), and thus the proportion of patients who were
spirin- or clopidogrel-resistant in our study could have
een different with other assays, which might have altered
ur study conclusions. However, we believe that the Veri-
yNow assays were well-suited for our study, because they
re the most commonly used point-of-care platelet assays
urrently available and were used in all 3 studies that had
reviously evaluated myonecrosis prevalence during PCI
1–3). Finally, we assessed only procedural and short-term
0-day clinical end points and thus do not know the
ong-term effects of aspirin and clopidogrel response on
ardiovascular events.onclusions
mong patients undergoing uncomplicated PCI with epti-
batide, the response to aspirin and clopidogrel did not
eem to affect periprocedural myonecrosis prevalence.
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